Biocon Biologics personnel working at the insulin devices manufacturing facility in Bengaluru, India.
Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe
November 30, 2023 05:00 ET | Biocon Biologics
BENGALURU, India, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris’...
SecureKloud Hosts Exclusive CIO Roundtable on the Future of Cloud Security and Compliance
July 27, 2023 06:00 ET | SecureKloud Technologies Limited
NEW DELHI, India, July 27, 2023 (GLOBE NEWSWIRE) -- SecureKloud Technologies, Inc., a global leader in cloud services delivering cloud excellence with unwavering security & trust, in association...
lupin logo.jpg
Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders
January 09, 2023 07:00 ET | Lupin Ltd
Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders Agreement enables sustainable...
Inauguration of  first TVS Experience Centre in Singapore
TVS Motor Company expands its global footprint; launches its first TVS Experience Centre in Singapore
November 24, 2022 02:45 ET | TVS Motor Company
SINGAPORE, Nov. 24, 2022 (GLOBE NEWSWIRE) -- TVS Motor Company, a reputed manufacturer of two-wheelers with sales of over three million units globally, today inaugurated its first state-of-the-art...
Coforge jpg.jpg
Coforge’s Copasys Automated Compliance Audit and Quality Assurance Platform Receives US Patent
September 29, 2022 11:57 ET | Coforge
GREATER NOIDA, India, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Coforge Limited (NSE: COFORGE), a global digital services and solutions provider, today announced it has been granted a US patent for its...
lupin logo.jpg
Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla®
February 09, 2022 07:23 ET | Lupin Ltd
Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla® Agreement enables expanded patient access of the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic...
lupin logo.jpg
Lupin’s Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)
November 04, 2021 08:31 ET | Lupin Ltd
FOR UK MEDICAL AND TRADE MEDIA ONLY Lupin’s Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) Slough, UK, 4...
lupin logo.jpg
Lupin responds to NICE Appraisal Consultation Document (ACD) on NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)
February 16, 2021 02:00 ET | Lupin Ltd
Lupin responds to NICE Appraisal Consultation Document (ACD) on NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) Slough, UK, 16th February...
lupin logo.jpg
Scottish Medicines Consortium approves Lupin's NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)
December 08, 2020 04:00 ET | Lupin Ltd
Scottish Medicines Consortium approves NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) Slough, UK, 8 December 2020: Lupin welcomes the...
adani-logo.png
Adani a été classé le plus important propriétaire de centrales solaires au monde
September 01, 2020 17:36 ET | Adani Green Energy
Son portefeuille mondial de 12,32 GWac dépasse la capacité totale installée de l'ensemble du secteur solaire aux États-Unis en 2019 SYNOPSIS Mercom Capital classe Adani Group au premier rang...